News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cara Therapeutics, Inc. (CARA) Initiates Phase 1a/1b Trial Of Tablet Formulation Of Oral CR845 For The Treatment Of Acute And Chronic Pain


6/18/2014 8:53:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SHELTON, Conn., June 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. The company expects to report top-line pharmacokinetic, safety and biomarker data in the fourth quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES